Effects of Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure: A Randomized Trial (CANDLE)
Atsushi Tanaka(Saga University), Koichi Node(Saga University), Itaru Hisauchi(Dokkyo Medical University Saitama Medical Center), Shinichiro Ueda(University of the Ryukyus), Jun‐ichi Oyama(Saga University), Akira Sezai(Nihon University), Masataka Sata(Tokushima University), Masafumi Kitakaze(National Cerebral and Cardiovascular Center), Isao Taguchi(Dokkyo Medical University Saitama Medical Center), Shigeru Toyoda(Dokkyo Medical University), Hirofumi Tomiyama(Kyushu University), Toyoaki Murohara(Nagoya University)
Cited by 109
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia.
|Journal of Clinical Investigation|1998|1.2k
Transplanted cord blood–derived endothelial precursor cells augment postnatal neovascularization
|Journal of Clinical Investigation|2000|892
Brachial-Ankle Pulse Wave Velocity and the Risk Prediction of Cardiovascular Disease
|Hypertension|2017|538
Physiological Diagnostic Criteria for Vascular Failure
|Hypertension|2018|282